ClinicalTrials.gg
TerminatedNCT00137345Updated Feb 8, 2013

Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients

A Phase 3 interventional study of sirolimus in Kidney Transplant, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Terminated at 82 sites in 21 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2013-02-08.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine if one drug is superior to another with regard to safety and the preservation of renal function after a kidney transplant.

02

Conditions studied

  • Kidney Transplant

Keywords

  • Randomized controlled trial
  • Clinical Trial Phase III
  • Drug therapy
  • Immunosuppression
  • Treatment outcome
  • Kidney transplantation
  • Kidney function tests
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dialysis patients who will be receiving their first kidney transplant
  • Weight over 88 pounds (lbs.)

Exclusion criteria

Exclusion Criteria:

  • Very high cholesterol levels
  • Obesity
  • Organ donor over 65 years of age if living; over 60 years of age if cadaveric.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants

Interventions

06

What researchers measure

Primary outcomes

  1. To demonstrate the superiority of the sirolimus regimen versus cyclosporin A by intent to treat analysis of kidney function at 52 weeks, measured by mean glomerular filtration rate (GFR)

  2. Non-inferiority of the composite of graft loss and death at 52 weeks

Secondary outcomes

  1. Incidence and severity of rejection at 12, 24, 52, 104, 156, 208 weeks; GFR at 24, 104, 156, 208 weeks; progression of chronic allograft nephropathy or deterioration of transplanted kidney at 52 weeks

  2. quality of life at 24, 52 and 104 weeks

07

Study locations

82 sites
  • San Diego, California 92123, United States
  • San Francisco, California 94143, United States
  • Denver, Colorado 80262, United States
  • New Haven, Connecticut 06520, United States
  • Gainesville, Florida 32610, United States
  • Tampa, Florida 33606, United States
  • Atlanta, Georgia 30309, United States
  • Chicago, Illinois 60612-3824, United States
  • Portland, Maine 04102, United States
  • Springfield, Massachusetts 01199, United States
  • Detroit, Michigan 48202, United States
  • New York, New York 10029, United States
  • Charlotte, North Carolina 28203, United States
  • Durham, North Carolina 27710, United States
  • Cleveland, Ohio 44106, United States
  • Cleveland, Ohio 44195, United States
  • Toledo, Ohio 43614, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Philadelphia, Pennsylvania 19129, United States
  • Providence, Rhode Island, United States
  • Charleston, South Carolina 29425, United States
  • Dallas, Texas 75246, United States
  • Houston, Texas 77225, United States
  • Buenos Aires, Capital Ferderal 1093, Argentina
  • Buenos Aires, Capital Ferderal 1155, Argentina
  • Buenos Aires, Capital Ferderal 1425, Argentina
  • Buenos Aires, Capital Ferderal C1118AT, Argentina
  • Buenos Aires, Capital Ferderal C1425APQ, Argentina
  • Buenos Aires, CP1900, Argentina
  • Ciudad de Bs As, Argentina
  • Cordoba, 5000, Argentina
  • Cordoba, Argentina
  • Camperdown, NSW 2050, Australia
  • Parkville, 3050, Australia
  • Randwick, 2031, Australia
  • Westmead, 2145, Australia
  • Woodville South, SA 5011, Australia
  • Woolloongabba, QLD 4102, Australia
  • Wien, A-1090, Austria
  • London, Ontario N6A 5A5, Canada
  • Cote du Palais, Quebec G1R 2J6, Canada
  • Montreal, Quebec H2L 4M1, Canada
  • Puente Alto, Chile
  • Santiago, Chile
  • Talca, Chile
  • Vina del Mar, Chile
  • Nicosia, 1102, Cyprus
  • Montpellier Cedex, 34059, France
  • Paris Cedex 15, 75747, France
  • Munster, 48149, Germany
  • Athens, 11527, Greece
  • Thessaloniki, 54642, Greece
  • Budapest, 1083, Hungary
  • Debrecen, 4012, Hungary
  • Pecs, 7621, Hungary
  • Szeged, 6720, Hungary
  • Bari, 70124, Italy
  • Cagliari, 09134, Italy
  • Torino, 10126, Italy
  • Oslo, 0027, Norway
  • Carnaxide-lisboa, 2795-563, Portugal
  • Coimbra, 3049, Portugal
  • Lisboa, 81050, Portugal
  • Singapore, 169608, Singapore
  • Cape Town, 7925, South Africa
  • Cape Town, 8001, South Africa
  • Johannesburg, 2193, South Africa
  • Barcelona, 08036, Spain
  • La Coruã'a, 15006, Spain
  • La Laguna / Santa Cruz de Tenerife, 38320, Spain
  • Madrid, 28040, Spain
  • Madrid, 28041, Spain
  • Santander, 39008, Spain
  • Valencia, 46009, Spain
  • Uppsala, SE-751 85, Sweden
  • Taipei, 100, Taiwan
  • Antalya, 07070, Turkey
  • Istanbul, 34390, Turkey
  • Izmir, 35100, Turkey
  • Glasgow, G11 6NT, United Kingdom
  • Leicester, LE5 4PW, United Kingdom
  • Manchester, M13 9WL, United Kingdom
08

References and documents

Publications

  • Flechner SM, Gurkan A, Hartmann A, Legendre CM, Russ GR, Campistol JM, Schena FP, Hahn CM, Li H, Korth-Bradley JM, Tai SS, Schulman SL. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients. Transplantation. 2013 May 27;95(10):1233-41. doi: 10.1097/TP.0b013e318291a269. PubMed 23689085 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2005
First posted
Aug 29, 2005
Start
Jun 2005
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Last update
Feb 8, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00137345
Responsible party
Sponsor
First posted
Aug 29, 2005
Start date
Jun 2005
Primary completion
Aug 2006
Completion
Aug 2006
Last update
Feb 8, 2013

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For Germany, MedInfoDEU@wyeth.com
Trial Manager
principal investigator · For Norway, Sweden, MedInfoNord@wyeth.com
Trial Manager
principal investigator · For Australia, Taiwan, medinfo@wyeth.com
Trial Manager
principal investigator · For Austria, WPVIMED@wyeth.com
Trial Manager
principal investigator · For Italy, Greece, decresg@wyeth.com
Trial manager
principal investigator · For Hungary, WPBUMED@wyeth.com
Trial Manager
principal investigator · For Turkey, Erisc@wyeth.com
Trial Manager
principal investigator · For South Africa, ZAFinfo@wyeth.com
Trial Manager
principal investigator · For Argentina, Chile, scheima@wyeth.com, rendop@wyeth.com
Trial Manager
principal investigator · For UK, ukmedonfo@wyeth.com
Trial Manager
principal investigator · For Switzerland, med@wyeth.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion